Clinical Trial Search

Primary: Length of Treatment With Opioid Medication — 19.1; 17.7 days

Primary: Length of Treatment — 15; 28 days — p=<0.05

Primary: Number of Participants With Neonatal Abstinence Syndrome — 22; 26 Participants — p=0.2

Primary: Length of Hospital Stay (LOS) — 21.8; 23.2 days

Primary: Buprenorphine Pharmacokinetics

Primary: Number of Participants With Skin Breakdown and / or Cellulitis — 0 participants

Primary: Enrollment Rate — 17 Participants

Primary: Time From Initiation of Adjunctive Therapy Until Hospital Discharge — 20; 33.8 Days

Primary: Length of Hospital Stay — 17.9; 16.1 days

Primary: Length of Hospitalization — 17.8; 11.4 days — p=0.03

Primary: Fetal Heart Rate at 24 Weeks — 143.64 beats per minute

Primary: Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) — 0.5; 0.3; 1.0; 0.6 score on a scale

Primary: Number of Participants Administered Morphine Treatment — 29; 31 Participants — p=.60

Primary: Number of Subjects With no Adverse Events Related to Bradycardia (HR < 80 Bpm), Worsening of Swallowing or Feeding, Skin Irritation, or Elevation of Neonatal Infant Pain…

Primary: Percentage of Infants Achieving a GI Subscore >2 Over the Study Period — 39; 61 Percentage of participants — p=0.001

Primary: Change in Finnegan Score — -1.5167; -0.2549 score on a scale

Primary: Fetal Heart Rate — 145.7; 143.3; 138.6; 136.3 beats per minute — p=0.001

Primary: Time From Birth Until Medically Ready for Discharge — 14.9; 8.2 days — p=<0.0001

Primary: Finnegan Neonatal Abstinence Scoring System — 7.5; 8.5; 6.6; 5.7 scores on a scale

Primary: Fetal Heart Rate — 142.34 beats per minute

Primary: Days of Treatment With Opioid Medication — 13.9; 22.9 days

Primary: Morphine Consumption — 0.014; 0.036 mg/kg/hr

Primary: Feasibility of the Intervention — 21.5; 21.2 score on a scale

Primary: Child's Head Circumference Measurement (Measured at Birth) — 33.0; 33.8 cm

Primary: Maternal Plasma Concentrations of Buprenorphine — 1.2; 1.7; 2.0; 2.4 ug/mL

Primary: Opioid Consumption — 31 milligrams of oxycodone

Primary: WIDEA Neurodevelopmental Outcome Score — 149.04; 162.46; 148.80; 151.89 score on a scale

Primary: Easing of Withdrawal Symptoms as Measured by the Withdrawal Assessment Tool (WAT-1) — 3.0; 3.0 Score on a scale

Primary: Heart Rate During Treatment With TENS Unit — 137; 131; 133; 133 beats per minute

Primary: Number of Participants With Adverse Events as a Measure of Safety and Feasibility — 3; 8; 4; 12 Participants